Satoreotide tetraxetan

DRUG2 trials

Sponsors

Ipsen

Conditions

Neuroendocrine TumorsSmall Cell Lung Cancer and Breast Cancer

Phase 1

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

TerminatedNCT02592707

IpsenNeuroendocrine Tumors

Start: 2017-03-06End: 2022-02-22Updated: 2023-07-19

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

TerminatedNCT03773133

IpsenSmall Cell Lung Cancer and Breast Cancer

Start: 2019-05-14End: 2019-10-10Updated: 2022-09-13

Related Papers

Dosimetry and pharmacokinetics of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.

2024-03-265 citations

A phase I/II study of the safety and efficacy of [<sup>177</sup>Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

2023-09-1817 citations